• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Immunol. Author manuscript; available in PMC Oct 1, 2012.
Published in final edited form as:
PMCID: PMC3362457
NIHMSID: NIHMS314156

Antimicrobial aspects of inflammatory resolution in the mucosa: A role for pro-resolving mediators1

Abstract

Mucosal surfaces function as selectively permeable barriers between the host and the outside world. Given their close proximity to microbial antigens, mucosal surfaces have evolved sophisticated mechanisms for maintaining homeostasis and preventing excessive acute inflammatory reactions. The role attributed to epithelial cells was historically limited to serving as a selective barrier, in recent years numerous findings implicate an active role of the epithelium with pro-resolving mediators in the maintenance of immunological equilibrium. In this brief review, we highlight new evidence that the epithelium actively contributes to coordination and resolution of inflammation, principally through the generation of anti-inflammatory and pro-resolution lipid mediators. These autacoids, derived from ω-6 and ω-3 polyunsaturated fatty acids, are implicated in the initiation, progression and resolution of acute inflammation and display specific, epithelial-directed actions focused on mucosalhomeostasis. We also summarize present knowledge of mechanisms for resolution via regulation of epithelial-derived antimicrobial peptides in response to pro-resolving lipid mediators.

General concepts of inflammatory resolution

The resolution of ongoing inflammation was historically considered a passive act of the healing process with dilution of pro-inflammatory chemical mediators (1) and occurred independent of active biochemical pathways (1, 2). This view has changed in fundamental ways in the past decade. It is now appreciated that uncontrolled inflammation is a unifying component in many diseases and new evidence indicates that inflammatory resolution is a biosynthetically active process (3). These new findings implicate a tissue decision process wherein acute inflammation, chronic inflammation, or inflammatory resolution hold the answers as to what endogenous mechanisms control the magnitude and duration of the acute response, particularly as they relate to the cardinal signs of inflammation (2, 4). It has now become evident that the resolution program of acute inflammation particularly within mucosal surfaces remains to be uncovered and that a complete understanding of these critical pathways will undoubtedly direct new therapeutic opportunities.

Inflammation at mucosal surfaces provides a unique setting for which to define resolution pathways. By their nature, mucosal surfaces interact with the environment and thereby the microbial world in which we live. Important in this regard, the microbiota of each mucosal surface is unique. It is estimated, for example, that the skin harbors 182 different bacterial species while the large intestine may support as many as 1220 different bacterial phylotypes (5). Given this diversity of microbiota, it is not surprising that humans have evolved unique mechanisms to counteract regular microbial challenges. Along these same lines, the timely resolution of ongoing local inflammation has evolved to these ever-changing challenges. We are only now beginning to appreciate the unique features and importance of these responses.

In this brief review, we highlight recent discoveries that impact the active resolution of mucosal inflammation. Given their founding role in active resolution mechanisms, we have focused on the unique contributions of specialized pro-resolving mediators (SPM), namely, the resolvins, lipid-derived mediators that are agonist-dependent, temporally distinct and functionally carry novel potent mucosa-directed signals (2).

Resolution-based pharmacology: a lesson from aspirin

Resolution of inflammation and return to tissue homeostasis is an exceptionally well-coordinated process. SPMs generated during the resolution phase of ongoing inflammation actively stimulate restoration of tissue homeostasis (3). The first resolvin, known today as resolvin E1 (RvE1), was identified in 1999 as a potent and active initiator of resolution (4). Inordinate, unrestricted acute inflammation is now acknowledged as an instigating factor, which when unchecked, contributes to numerous chronic disease states, including cardiovascular disease, metabolic disorders and cancer. As such, an understanding of the pharmacology of anti-inflammation and endogenous pro-resolution has been a significant venture (2).

As a basic feature, cyclooxygenase-2 (COX-2) contributes fundamentally to both inflammation and resolution (6, 7). COX-2 expression is rapidly induced at sites of inflammation and is a key enzyme in the generation of prostaglandins, via its oxygenase and peroxidase activities (7). Briefly, following liberation of the omega-6 fatty acid arachidonic acid (AA) from cell membranes via PLA2, the oxygenase function of COX-2 catalyzes AA to PGG2 and subsequently to PGH2 via the peroxidase activity of the enzyme. Non-steroidal anti-inflammatory drugs (NSAIDs) lower the amplitude of inflammation and delay resolution (6, 8). Acetylsalicylic acid (ASA, aspirin), stands apart in that it inhibits pro-inflammatory signals and accelerates resolution (9). ASA irreversibly acetylates COX-2 on serine 516 rendering it incapable of converting AA to PGG2. In its acetylated state, ASA produces 15RH(P)ETE and its peroxidase activity remains intact resulting in formation of 15R-hydroxyeicosatetraenoate (15R-HETE). Aside from ASA's anti-inflammatory action of inhibiting prostaglandin synthesis, 15R-HETE is a precursor for pro-resolution 15-epi-lipoxins (10). Such aspirin-triggered lipoxins (ATLs) are more resistant to metabolic inactivation than lipoxins (11) and also assert anti-inflammatory and pro-resolving activities in a wide range of inflammatory diseases (7, 8). In addition to the arachidonate-derived lipoxins and ATLs, bioactive SPMs are also biosynthesized from the omega-3 polyunsaturated fatty acids (PUFAs). Both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are precursors in the biosynthesis of both AT- forms of the E- and D-series resolvins. Of Importance, lipoxygenases (LOXs) can initiate the biosynthesis of resolvins (both E- and D-series) as well as protectins and maresins without ASA treatment (3)(see Figure 1). These are the main pathways for SPM biosynthesis in the absence of ASA treatment. Other NSAIDs i.e. indomethacin can both block the biosynthesis of the AT-forms of SPM but also lead to enhanced formation of SPM via the lipoxygenase routes involved in the biosynthesis of specific SPM. The biosynthesis of SPM has recently been reviewed in detail and those interested should see (12).

Figure 1
“Class switching” in the lipid metabolome promotes resolution

Active resolution: Biosynthesis of SPM

Resolution of acute self-limited inflammation is distinct, by definition, from anti-inflammatory process (3). Pro-resolving mediators restrict further infiltration of PMN to sites of acute inflammation and promote resolution via enhancing clearance of apoptotic cells by macrophages (3). Importantly, pro-resolving mediators stimulate antimicrobial activites of epithelia (13, 14), aiding a return to tissue homeostasis. These are particularly relevant in the eye, lung and oral epithelial surfaces. For example, RvE1 reduces ocular herpes simplex induced inflammation (15) and PD1 reduces ocular epithelial injury (16), RvD1, RvE1 and Protectin D1 each reduce airway inflammation (17-20) and RvE1 reduces oral inflammation of the peridontium (21) as well as stimulates the clearance of apoptotic cell from mucosal surfaces (22). The protective role of RvE1 in periodontal disease has been attributed to both diminished inflammation and curtailed osteoclast-dependent destruction of bone (23). In the gastrointestinal tract, RvE1 is protective in murine models of colitis (13, 24-26). Moreover, RvE1 and RvD1 have been recently implicated in the alleviation of inflammatory pain (27). Thus, the potential therapeutic benefits of SPMs are far-reaching.

Much recent attention has been paid to understanding the innate mechanisms involved in the resolution of inflammation at mucosal sites. The best understood are the families of lipid mediators termed the resolvins (Rv) and the maresins (MaR) (2). Resolvins have been studied in most detail and are omega-3 polyunsaturated fatty acids (omega-3 PUFA)-derived lipid mediators central to activation of the inflammatory resolution program (2, 3). The discovery of resolvins was permitted by using an unbiased systems approach to acute contained self-limited / naturally resolving inflammatory exudates using LC-MS-MS-based lipidomics and earlier knowledge that omega-3 PUFA are beneficial to a number of cardiovascular and immunoregulatory responses (9). Ensuing studies revealed the existence of novel families of lipid mediators, derived from either eicosapentaenoic acid (C20:5, 18-series resolvins) as well as docosahexaenoic acid (C22:6, 17-series resolvins), which potently and stereoselectively initiate and enhance the resolution mechanisms in acute inflammation.

Mechanisms of SPM-mediated resolution

To date, an array of SPMs are identified with potent pro-resolution activities, their mechanisms of action are equally diverse. ATL (15-epi-lipoxin) binds to the LXA4 receptor (ALX/FPR2; Formyl Peptide Receptor 2), eliciting antagonistic activities on PMN chemotaxis (28). RvE1 binds to and interacts with ChemR23 receptor resulting in ERK and AKT phosphorylation and subsequent signal transduction via ribosomal protein S6 to enhance macrophage phagocytosis (29). RvE1 also binds to the LTB4 receptor, BLT1 on neutrophils where it acts as a partial agonist (30). Aside from signal transduction directly affecting leukocyte function, modulation of gene expression in response to SPM has revealed key insight to their mechanism of resolution. Lipoxin A4 and Resolvin E1 induce CCR5 expression on the surface of apoptotic PMN and T-cells, resulting in sequestration of CCL3/CCL5 in murine peritonitis, facilitating resolution (31). RvE1 and RvD1 both attenuate PMN transmigration across endothelia (32, 33). Furthermore, RvE1 accelerates the clearance apically-adherent PMN from epithelia by enhancing anti-adhesive CD55 expression (22). Likewise, ATL induces the expression of an anti-microbial peptide, bactericidalpermeability enhancing (BPI), in epithelial cells (14). Also, RvD2 enhances phagocyte killing of microbes, improving survival in cecal ligation puncture-initiated sepsis (34) and RvD1 modulates macrophage responses to LPS-TLR4 signaling, resulting in decreased pro-inflammatory cytokine release, whilst maintaining IL-10 expression (35).

More recently RvE1 was discovered to upregulate the expression of intestinal alkaline phosphatase (ALPI), a marker of differentiation with a surprising role in maintenance of bacterial homeostasis (13). Given the proximity of mucosal surfaces to bacterial antigens, the vital role of antimicrobial peptides (AMPs) in host defense, we will discuss the potential role for AMPs in the process of resolution.

Antimicrobial peptides in the mucosa

Epithelial cells are uniquely positioned to serve as a direct line of communication between the immune system and the external environment. In their normal state, mucosal surfaces are exposed on the lumenal surface to high concentrations of foreign antigens, while at the same time, intimately associated with the immune system via subepithelial lymphoid tissue (36). Polarized epithelia form a physical selective barrier to allow absorption/secretion while preventing entry of pathogens into the body. The mucosal epithelium comprises a heterogeneous population of differentiated epithelia with distinct functions: absorptive enterocytes, mucus secreting goblet cells, antimicrobial peptide secreting Paneth cells and enteroendocine cells (37).

Antimicrobial peptides (AMPs) are secreted prophylactically by the epithelium into the viscous mucus layer, thus minimizing the instance of epithelium-adhering bacteria. Similarly, Paneth cells secrete antimicrobial peptides (defensins/lectins) maintaining intestinal crypt sterility. Consequently, the epithelium forms an important barrier, preventing the free mixing of lumenal antigenic material with the lamina propria which houses the mucosal immune system (38) and defects in these defensive functions contributes to disease pathogenesis (e.g. loss of function in mucin-2 / Paneth cells can contribute to inflammatory bowel disease) (39). Concordantly, AMP generation provides protection for other mucosal epithelial surfaces: lung epithelia produce defensins and LL-37 (40), corneal and conjunctival epithelia express LL-37 (41) and oral epithelia are protected by AMPs secreted in saliva (42, 43).

Like many aspects of immunology, the view that the epithelium is merely a physical selective-barrier has changed. The epithelium is now viewed as an active player in normal homeostatic mechanisms of mucosal immunity, and in some instances, the epithelium may centrally orchestrate mucosal innate immunity and inflammation (44).

“Classical” AMPs

The classically viewed AMP's represent a diverse array of small peptides (12-50 amino acids), containing a positive charge and an amphipathic structure. The most studied AMPs to date are cathelicidins and defensins. Cathelicidin (LL-37) is expressed by epithelial cells, neutrophils, monocytes and macrophages and can stimulate chemotaxis via the ALX/FPR2 receptor on these cells (45). Post-translational processing is essential for its antimicrobial activity in vivo (46) and is accomplished by serine proteases such as kallikreins (47) or PMN proteases such as proteinase-3 (48). LL-37 antimicrobial activity was originally thought to neutralize endotoxin due to its cationic/amphipathic capacities to interact with anionic lipopolysaccharide or prevent LPS binding to CD14 (49). Aside from preventing sepsis by interfering with the ability of LPS to stimulate TLR4 signaling, LL-37 have subsequently been demonstrated to directly dampen pro-inflammatory signaling initiated by LPS (50). Mice deficient in the only known murine cathelicidin (encoded by the gene Cnlp) show significant increases in susceptibility to a number of mucosal infections (51).

Defensins are cationic antimicrobial peptides broadly classed as alpha- and beta-defensins, the former predominantly expressed by PMN and Paneth cells, the latter by epithelia (52). Similar to LL-37s, alpha-defensins are activated by proteolytic processing of an inactive precursor (53) and are stored in granules of PMN. In contrast to alpha-defensins, beta-defensins typically have short amino-terminal extensions and all possess some measure of antimicrobial activity in their full-length forms. Defensins have broad antimicrobial actions on Gram positive and Gram negative bacteria and defects in defensin expression have been shown to contribute to a number of mucosal inflammatory diseases, including inflammatory bowel disease and necrotizing enterocolitis (54). Beta-defensins are secreted in saliva and are thought to be protective against peridontitis and caries (43). Mutations of the 3’-untranslated region of beta defensin leads to chronic and aggressive peridontitis (55).

Immuno-modulatory functions of AMPs

Given their name, antimicrobial peptides were originally thought to function merely as “natural antibiotics”, specialized in the killing of bacteria. This bias has hampered discovery of their diverse array of function in immunity and their regulation in host defense. Increasing evidence indicates that aside from their antimicrobial activity, AMPs can modulate immune responses by inducing cytokine/chemokine production, inhibiting LPS-induced pro-inflammatory cytokine production, promoting wound healing and modulating the responses of dendritic cells or T-cells. As such, AMPs may be viewed as bridging the gap between innate and adaptive immunity.

Cathelicidin has immuno-modulatory functions, for instance, is chemotactic to mast cells and PMN via interaction with the ALX/FPR2 receptor (45, 56), which is blocked by the anti-inflammatory LXA4 stable analog. Cathelicidin stimulates release of the anti-inflammatory prostaglandin PGD2 from mast cells (57), which as mentioned above can prime tissues for resolution by expressing enzymes necessary for resolution. Human beta-defensin 2 also possesses immuno-modulatory functions and like LL-37, is known to be chemotactic for mast cells and activated PMN (58). Beta-defensin 3 upregulates COX-2 and PGE2 biosynthesis in gingival fibroblasts (59). Beta-defensins antagonize T-cell tissue infiltration and promote exfiltration (60, 61). Considering their rapid release in response to “danger signals” and their consequent immunomodulatory activities, has led to the concept that AMPs can act as early warning signals for infection and the creation of term “alarmins” (62).

AMP's and restitution / wound closure

As part of their pro-resolving activity, both LL-37 (63, 64) and beta-defensin 2 (65) are known to promote epithelial cell migration, necessary for mucosal restitution following physical injury or damage from immune activity. Human beta-defensin 2 stimulates migration and proliferation and tube formation of endothelial cells in wounds, resulting in neovascularization and accelerated wound healing (66). LL-37 has been proposed to initiate tissue remodeling via matrix metalloproteinase activity and promote wound closure via induction of the Snail/Slug transcription factors, necessary for E-cadherin transcription and epithelial adherens junction formation (64).

“Non-classical” AMPs

Bactericidal permeability-increasing protein (BPI)

A number of additional mechanisms exist to maintain homeostasis at mucosal surfaces. Among the innate antimicrobial defense molecules of humans is BPI, a 55-60 kDa protein originally found in neutrophil azurophilic granules, on the neutrophil cell surface, and to a lesser extent, in specific granules of eosinophils (67). Subsequently, BPI was found to be expressed in epithelial cells (14). Based on an original transcriptional profiling approach to identify novel aspirin-triggered lipoxin (ATL)-regulated genes in intestinal epithelial cells, BPI was found to be expressed in both human and murine epithelial cells of wide origin (oral, pulmonary, and gastrointestinal mucosa) and each was similarly regulated by ATL. Functional studies employing a BPI-neutralizing anti-serum revealed that surface localized BPI blocks endotoxin-mediated signaling in epithelia and kills Salmonella typhimurium. More recently, molecular studies revealed that epithelial BPI is selectively induced by ATL and prominently regulated by the transcription factors Sp1/3 and C/EBPβ (68). Additional studies in human and murine tissue ex vivo revealed that BPI is diffusely expressed along the crypt-villous axis (14, 68), and that epithelial BPI protein levels decrease along the length of the intestine (69). More recent studies with SPM have revealed the expression of BPI in various mucosal epithelia (67).

As its name infers, BPI selectively exerts multiple antimicrobial actions against gram-negative bacteria, including cytotoxicity through damage to bacterial inner / outer membranes, neutralization of bacterial lipopolysaccharide (endotoxin), as well as serving as an opsonin for phagocytosis of gram-negative bacteria by neutrophils (70, 71). The high affinity of BPI for the lipid A region of LPS (72) targets its cytotoxic activity to Gram-negative bacteria. Binding of BPI to the Gram-negative bacterial outer membrane is followed by a time-dependent penetration of the molecule to the bacterial inner membrane where damage results in loss of membrane integrity, dissipation of electrochemical gradients, and bacterial death (73). BPI binds the lipid A region of LPS with high affinity (74, 75) and thereby prevents its interaction with other (pro-inflammatory) LPS-binding molecules, including LBP and CD14 (76). Since BPI binds the lipid A region common to all LPS, it is able to neutralize endotoxin from a broad array of Gram-negative pathogens (71). The selective and potent action of BPI against Gram-negative bacteria and their LPS is fully manifest in biologic fluids, including plasma, serum, and whole blood (71, 77). In multiple animal models of Gram-negative sepsis and/or endotoxemia, administration of BPI congeners is associated with improved outcome (78, 79). These studies in epithelia have identified a previously unappreciated “molecular shield” for protection of mucosal surfaces against Gram-negative bacteria and their endotoxin.

Intestinal alkaline phosphatase (ALPI)

There is much recent interest in ALPI, a 70 kDa, GPI-anchored protein expressed on the apical (luminal) aspect of intestinal epithelial cell (80). In the past, this molecule had been viewed as one of the better epithelial differentiation markers, with little understanding of the true function of this molecule within the mucosa. More recent studies have identified this molecule as a central player in microbial homeostasis (81-83).

A recent microarray screen to identify RvE1-regulated genes in intestinal epithelial cells revealed two important findings. First, these studies revealed the previously unappreciated native expression of the RvE1 receptor ChemR23 on epithelial cells. A screen of various epithelial cell lines revealed prominent expression of ChemR23 on human intestinal epithelial cell lines (T84 and Caco-2). Unique was the pattern of expression on polarized epithelia. This analysis revealed that ChemR23 localizes predominantly to the apical membrane surface, which was somewhat unexpected given that most other G-protein-coupled receptors exhibit basolateral expression in polarized epithelia (84). Such membrane distribution of ChemR23 suggested that the localized generation of RvE1 during PMN-epithelial interactions could occur at the apical (lumenal) aspect of the tissue. This is an intriguing possibility given that the other known function for RvE1 on mucosal epithelia is to promote the termination and clearance of PMN following transmigration (22), through well-characterized CD55-dependent mechanisms (85, 86). Thus, the PMN-epithelial interactions that occur within the lumen of the intestine may initiate a pro-resolving signature to the epithelium during PMN transit through the mucosa.

Second, these microarray studies identified a prominent RvE1-dependent antimicrobial signature within the epithelium, including the induction of BPI and the BPI-like molecule PLUNC (palate, lung, nasal epithelium clone) (13). Also notable was the induction of epithelial ALPI by RvE1. Surface expressed ALPI was shown to retard Gram negative bacterial growth and to potently neutralize LPS through a mechanism involving dephosphorylation of 1,4’-bisphosphorylated glucosamine disaccharide of LPS lipid A (82, 83). This observation was translated to the murine model DSS colitis and revealed that induction of ALPI by RvE1 in vivo strongly correlated with the resolution phase of inflammation (Figure 2). Moreover, inhibition of ALPI activity was shown to increase the severity of colitic disease and abrogated the protective influences of RvE1 (13). Like those defining epithelial expression of BPI (14), these studies provide an example of the critical interface between inflammatory resolution and the importance of antimicrobial mechanisms.

Figure 2
RvE1 biosynthesis and model for induction of epithelial ALPI

Conclusions

Given the close proximity of bacteria to mucosal surfaces, maintenance of tissue homeostasis presents a significant challenge. Following successful handling of infiltrating bacteria, the generation of pro-resolving mediators accelerates the return to homeostasis. This review highlights not only the multi-functional role of AMPs in inflammation, but also the inter-dependent relationship between the induction of AMPs and the initiation of resolution pathways and the role of resolvins in this process (see Figure 3). Following microbial detection, “alarmins” or “classical” AMPs are released by infiltrating immune cells, aiding the killing of bacteria, stimulating neutrophils to generate reactive oxygen species (with inadvertent tissue damage), promoting further release of AMPs and releasing both pro- and anti-inflammatory lipids via COX-2 induction. As such “classical” AMPs could be considered to have both pro- and anti-inflammatory properties, suggesting that AMPs prime the inflammatory microenvironment of the mucosal surface for resolution. Following generation of SPM, “non-classical” AMPs may accelerate return to homeostasis via continued bacterial killing, inhibition of LPS signaling and inhibition of “classical” AMP release from leukocytes. As such, it would appear that an interdependent relationship exists between the activity of AMPs and the initiation of resolution programs. Along these lines, RvE1 blocks LTB4-stimulated release of LL-37 by human PMN and LXA4 inhibits proinflammatory actions of LL-37 (45).

Figure 3
Temporal regulation and multi-functional roles of SPM-regulated AMPs in the resolution of inflammation

Overall, the contribution of microbes to health and disease has provided an elegant lesson in biology. Results from model disease systems and humans allowed the discovery of pro-resolving mechanisms that are fundamental to our understanding of disease pathogenesis. As summarized in this review, the interdependence of antimicrobial defense mechanisms with inflammatory disease resolution have provided an informative example of how these biochemical pathways yield insight toward a better understanding of tissue function. Ongoing studies of antimicrobial regulation in the mucosa, exemplified by SPM-regulated BPI and ALPI in intestinal epithelia, should provide templates for the design of new and effective therapies for inflammatory disease resolution.

Abbreviations

ALPI
intestinal alkaline phosphatase
AMP
antimicrobial peptide
ATL
aspirin-triggered lipoxin
BPI
bactericidal permeability-increasing protein
DHA
Docosahexaenoic acid
EPA
Eicosapentaenoic acid
LXA4
lipoxin A4 (5S,6R,15S- trihydroxytrihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid)
PMN
polymorphonuclear leukocyte, neutrophil
RvD2
resolvin D2 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid)
RvE1
resolvin E1 (5S,6R,15S- trihydroxytrihydroxy 7E,9E,11Z,13E-eicosatetraenoic acid)
SPM
specialized pro-resolving mediator

Footnotes

1E.L.C. is supported by a fellowship from the Crohn's and Colitis Foundation of America. S.P.C. lab is supported by NIH grants R37DK50189 and RO1HL60569. C.N.S. lab is supported in part by NIH grants R01GM038765 and R01DE019938. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of General Medical Sciences, the National Heart Lung and Blood Institute, the National Institute of Dental and Craniofacial Research, or the National Institutes of Health.

Conflict of Interest and Funding Disclosure: E.L.C. declares no conflict of interest related to this work. S.P.C. and C.N.S. are inventors on patents assigned to BWH-Partners HealthCare on the composition, uses, and clinical development of anti-inflammatory and pro-resolving mediators and related compounds. These are licensed for clinical development: lipoxins to Bayer HealthCare, resolvins and related materials to Resolvyx Pharmaceuticals. C.N.S. retains founder stock in Resolvyx, he declares no other competing financial interests.

References

1. Majno G, Joris I. Cells, Tissues and Disease: Principles of General Pathology. Blackwell Science; Cambridge, Mass: 1996.
2. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 153 Suppl. 2008;1:S200–215. [PMC free article] [PubMed]
3. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–361. [PMC free article] [PubMed]
4. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–1204. [PMC free article] [PubMed]
5. Bik EM. Composition and function of the human-associated microbiota. Nutr Rev. 2009;67:S164–171. [PubMed]
6. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cycloxygenase may have anti-inflammatory properties. Nat Med. 1999;5:698–701. [PubMed]
7. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2011;107:1170–1184. [PMC free article] [PubMed]
8. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007;447:869–874. [PMC free article] [PubMed]
9. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325–332. [PMC free article] [PubMed]
10. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92:9475–9479. [PMC free article] [PubMed]
11. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, Colgan SP, Madara JL. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry. 1995;34:14609–14615. [PubMed]
12. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta. 2010;1801:1260–1273. [PMC free article] [PubMed]
13. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A. 2010;107:14298–14303. [PMC free article] [PubMed]
14. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP. Lipid mediator-induced expression of bactericidal/ permeability- increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A. 2002;99:3902–3907. [PMC free article] [PubMed]
15. Rajasagi NK, Reddy PB, Suryawanshi A, Mulik S, Gjorstrup P, Rouse BT. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J Immunol. 2011;186:1735–1746. [PMC free article] [PubMed]
16. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem. 2005;280:15267–15278. [PubMed]
17. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun. 2008;367:509–515. [PubMed]
18. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol. 2008;9:873–879. [PMC free article] [PubMed]
19. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 2007;178:496–502. [PMC free article] [PubMed]
20. Wang B, Gong X, Wan JY, Zhang L, Zhang Z, Li HZ, Min S. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm Pharmacol Ther. 2011;24:434–441. [PubMed]
21. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol. 2007;179:7021–7029. [PubMed]
22. Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 2007;21:3162–3170. [PubMed]
23. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. Faseb J. 2006;20:401–403. [PubMed]
24. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005;102:7671–7676. [PMC free article] [PubMed]
25. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. {omega}-3 Fatty Acid-Derived Mediators 17(R)-Hydroxy Docosahexaenoic Acid, Aspirin-Triggered Resolvin D1 and Resolvin D2 Prevent Experimental Colitis in Mice. J Immunol. 2011 [PubMed]
26. Lima-Garcia J, Dutra R, da Silva K, Motta E, Campos M, Calixto J. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol. 2011 [PMC free article] [PubMed]
27. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med. 2010;16:592–597. 591p following 597. [PMC free article] [PubMed]
28. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997;185:1693–1704. [PMC free article] [PubMed]
29. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010;285:3451–3461. [PMC free article] [PubMed]
30. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178:3912–3917. [PubMed]
31. Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, Luster AD, Serhan CN. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol. 2006;7:1209–1216. [PMC free article] [PubMed]
32. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025–1037. [PMC free article] [PubMed]
33. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, Colgan SP, Petasis NA, Serhan CN. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323–9334. [PubMed]
34. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461:1287–1291. [PMC free article] [PubMed]
35. Palmer CD, Mancuso CJ, Weiss JP, Serhan CN, Guinan EC, Levy O. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol. 2011 [PMC free article] [PubMed]
36. Beagley KW, Husband AJ. Intraepithelial lymphocytes: origins, distribution, and function. Crit Rev Immunol. 1998;18:237–254. [PubMed]
37. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2008;14:401–407. [PMC free article] [PubMed]
38. McCole DF, Barrett KE. Varied role of the gut epithelium in mucosal homeostasis. Curr Opin Gastroenterol. 2007;23:647–654. [PubMed]
39. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12:319–330. [PMC free article] [PubMed]
40. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB., Jr. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A. 1998;95:14961–14966. [PMC free article] [PubMed]
41. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005;30:385–394. [PMC free article] [PubMed]
42. Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA. Expression of the antimicrobial peptide, human beta-defensin 1, in duct cells of minor salivary glands and detection in saliva. J Dent Res. 2000;79:1669–1674. [PubMed]
43. Abiko Y, Nishimura M, Kaku T. Defensins in saliva and the salivary glands. Med Electron Microsc. 2003;36:247–252. [PubMed]
44. Shale M, Ghosh S. How intestinal epithelial cells tolerise dendritic cells and its relevance to inflammatory bowel disease. Gut. 2009;58:1291–1299. [PubMed]
45. Wan M, Godson C, Guiry PJ, Agerberth B, Haeggström JZ. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counter-regulated by lipoxin A4 and resolvin E1. FASEB J. 2011;25:1697–1705. [PubMed]
46. Cole AM, Shi J, Ceccarelli A, Kim YH, Park A, Ganz T. Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood. 2001;97:297–304. [PubMed]
47. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, Bonnart C, Descargues P, Hovnanian A, Gallo RL. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006;20:2068–2080. [PubMed]
48. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood. 1997;90:2796–2803. [PubMed]
49. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem. 2006;281:1636–1643. [PubMed]
50. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol. 2006;176:2455–2464. [PubMed]
51. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol. 2005;174:4901–4907. [PubMed]
52. van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS. Defensins: key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol. 1999;104:1131–1138. [PubMed]
53. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999;286:113–117. [PubMed]
54. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol. 2007;19:70–83. Epub 2007 May 2007. [PubMed]
55. Schaefer AS, Richter GM, Nothnagel M, Laine ML, Ruhling A, Schafer C, Cordes N, Noack B, Folwaczny M, Glas J, Dorfer C, Dommisch H, Groessner-Schreiber B, Jepsen S, Loos BG, Schreiber S. A 3' UTR transition within DEFB1 is associated with chronic and aggressive periodontitis. Genes Immun. 2010;11:45–54. [PubMed]
56. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069–1074. [PMC free article] [PubMed]
57. Niyonsaba F, Hirata M, Ogawa H, Nagaoka I. Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells. Curr Drug Targets Inflamm Allergy. 2003;2:224–231. [PubMed]
58. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol. 2002;14:421–426. [PubMed]
59. Chotjumlong P, Khongkhunthian S, Ongchai S, Reutrakul V, Krisanaprakornkit S. Human beta-defensin-3 up-regulates cyclooxygenase-2 expression and prostaglandin E2 synthesis in human gingival fibroblasts. J Periodontal Res. 2010;45:464–470. [PubMed]
60. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol. 2006;177:782–786. [PubMed]
61. Ghannam S, Dejou C, Pedretti N, Giot JP, Dorgham K, Boukhaddaoui H, Deleuze V, Bernard FX, Jorgensen C, Yssel H, Pene J. CCL20 and beta-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol. 2010;186:1411–1420. [PubMed]
62. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17:359–365. [PubMed]
63. Otte JM, Zdebik AE, Brand S, Chromik AM, Strauss S, Schmitz F, Steinstraesser L, Schmidt WE. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept. 2009;156:104–117. [PubMed]
64. Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, Retamosa L, Jorcano JL, Rio MD, Larcher F. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol. 2008;128:223–236. [PubMed]
65. Otte JM, Werner I, Brand S, Chromik AM, Schmitz F, Kleine M, Schmidt WE. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem. 2008;104:2286–2297. [PubMed]
66. Baroni A, Donnarumma G, Paoletti I, Longanesi-Cattani I, Bifulco K, Tufano MA, Carriero MV. Antimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides. 2009;30:267–272. [PubMed]
67. Canny G, Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol. 2008 [PubMed]
68. Canny G, Cario E, Lennartsson A, Gullberg U, Brennan C, Levy O, Colgan SP. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am J Physiol Gastrointest Liver Physiol. 2006;290:G557–567. [PubMed]
69. Canny GO, Trifonova RT, Kindelberger DW, Colgan SP, Fichorova RN. Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. J Infect Dis. 2006;194:498–502. [PubMed]
70. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol. 1998;10:45–49. [PubMed]
71. Levy O. A neutrophil-derived anti-infective molecule: bactericidal/permeability- increasing protein. Antimicrob Agents Chemother. 2000;44:2925–2931. [PMC free article] [PubMed]
72. Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Parsons T, Theofan G, Elsbach P, Weiss J, Conlon PJ. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun. 1992;60:4754–4761. [PMC free article] [PubMed]
73. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest. 1990;85:853–860. [PMC free article] [PubMed]
74. Levy O, Ooi CE, Elsbach P, Doerfler ME, Lehrer RI, Weiss J. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol. 1995;154:5403–5410. [PubMed]
75. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol. 1999;11:19–22. [PubMed]
76. Gazzano-Santoro H, Meszaros K, Birr C, Carroll SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun. 1994;62:1185–1191. [PMC free article] [PubMed]
77. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem. 1978;253:2664–2672. [PubMed]
78. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J Infect Dis. 1995;171:153–160. [PubMed]
79. Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob Agents Chemother. 1996;40:65–69. [PMC free article] [PubMed]
80. Vaishnava S, Hooper LV. Alkaline phosphatase: keeping the peace at the gut epithelial surface. Cell Host Microbe. 2007;2:365–367. [PubMed]
81. Goldberg RF, Austen WG, Jr., Zhang X, Munene G, Mostafa G, Biswas S, McCormack M, Eberlin KR, Nguyen JT, Tatlidede HS, Warren HS, Narisawa S, Millan JL, Hodin RA. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A. 2008;105:3551–3556. [PMC free article] [PubMed]
82. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316:1628–1632. [PubMed]
83. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15:506–516. [PubMed]
84. Wozniak M, Keefer JR, Saunders C, Limbird LE. Differential targeting and retention of G protein-coupled receptors in polarized epithelial cells. J Recept Signal Transduct Res. 1997;17:373–383. [PubMed]
85. Lawrence DW, Bruyninckx WJ, Louis NA, Lublin DM, Stahl GL, Parkos CA, Colgan SP. Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia. J Exp Med. 2003;198:999–1010. [PMC free article] [PubMed]
86. Louis NA, Hamilton KE, Kong T, Colgan SP. HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J. 2005;19:950–959. [PubMed]
87. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101–137. [PubMed]
88. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011;121:569–581. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...